Mergers and acquisitions
News/ News/ Sales and Marketing
Saunders steps aside as AbbVie closes in on Allergan merger
Phil Taylor
AbbVie, Allergan, Mergers and acquisitions, regulatory
0 Comment
News/ News/ News/ Oncology/ Sales and Marketing/ Top stories
Menarini bags blood cancer drug with $677M Stemline acquisition
Phil Taylor
Elzonris, Haematology, Menarini Group, Mergers and acquisitions, Oncology, rare disease, Stemline Therapeutics
0 Comment
News/ News/ Sales and Marketing/ Top stories
Antitrust delay scuppers Novartis’ $1bn generics sale to Aurobindo
Phil Taylor
Aurobindo, generic, Mergers and acquisitions, Novartis
0 Comment
Lilly swoops on Dermira to claim Dupixent rival
Phil Taylor
atopic dermatitis, dermatology, Dermira, Dupixent, Eli Lilly, Mergers and acquisitions, Regeneron, Sanofi
0 Comment
News/ News/ News/ R&D/ Sales and Marketing/ Top stories
Sumitomo, Roivant close $3 billion deal, forming Sumitovant
Phil Taylor
Mergers and acquisitions, Roivant, Sumitomo Dainippon Pharma, Sumitovant Bopharma
0 Comment
News/ News/ Sales and Marketing
Pfizer confirms generic medicines merger with Mylan
Phil Taylor
generics, Mergers and acquisitions, Mylan, Pfizer
0 Comment
BMS will shed Otezla to push Celgene takeover through
Phil Taylor
Bristol-Myers Squibb, Celgene, Mergers and acquisitions, Otezla, psoriasis
0 Comment
News/ News/ R&D/ R&D/ UK & Europe
Sanofi steals in to buy Ablynx for €3.9 billion
Andrew McConaghie
Ablynx, European biotech, M&A, Mergers and acquisitions, Sanofi
0 Comment